Ad
CHRS - Coherus BioSciences Stock Trading
About | Coherus BioSciences Inc. (NASDAQ:CHRS)
Not available
Quote | Coherus BioSciences Inc. (NASDAQ:CHRS)
| Last: | $2.2455 |
|---|---|
| Change Percent: | 5.42% |
| Open: | $2.13 |
| Close: | $2.13 |
| High: | $2.27 |
| Low: | $2.02 |
| Volume: | 1,691,945 |
| Last Trade Date Time: | 12/01/2023 03:00:00 am |
News | Coherus BioSciences Inc. (NASDAQ:CHRS)
-
2023-12-01 10:17:15 ET The UBS pharma equity team is out with a quant list of most crowded stocks on the long and short side. Crowding is a sentiment metric that basically measure popularity in positioning (long or short). It indicates if a stock has a significantly above-average number...
-
2023-11-28 13:35:38 ET More on Coherus BioSciences Coherus BioSciences Is A Buy On The Dip After Toripalimib Approval Coherus: The Surface Acquisition Is A Distraction Coherus BioSciences, Inc. (CHRS) Q3 2023 Earnings Call Transcript Coherus stock rises as Ba...
Message Board Posts | Coherus BioSciences Inc. (NASDAQ:CHRS)
| Subject | By | Source | When |
|---|---|---|---|
| MomentumIts gaining last up | DewDiligence | investorshub | 05/09/2023 8:42:13 PM |
| $CHRS good read | DewDiligence | investorshub | 05/08/2023 4:47:45 PM |
| short data if anyone is interested | dinogreeves | investorshub | 05/08/2023 11:07:14 AM |
| should we be shorting? | DewDiligence | investorshub | 05/08/2023 6:16:37 AM |
| $CHRS must see | dinogreeves | investorshub | 05/08/2023 5:57:13 AM |
News, Short Squeeze, Breakout and More Instantly...
Coherus BioSciences Inc. Company Name:
CHRS Stock Symbol:
NASDAQ Market:
Coherus BioSciences Inc. Website:
Ad
-
– Final overall survival analysis of the JUPITER-02 trial shows first-line treatment with LOQTORZI plus chemotherapy significantly prolongs survival in patients with recurrent or metastatic NPC irrespective of PDL-1 status– – Treatment resulted in a 37% reduction in...
-
2023-11-10 15:15:37 ET A disappointing quarter combined with a set of analyst price target cuts -- and even a recommendation downgrade -- made Coherus BioSciences (NASDAQ: CHRS) a stock to avoid this week. As of mid-afternoon Friday, according to data compiled by S&P Global Ma...
-
Key Takeaways: Junshi Bio will receive milestone payments and 20% of sales of its PD-1 drug Toripalimab in the U.S., following the drug’s re...